Predicted effect of ticagrelor on the pharmacokinetics of dabigatran etexilate using physiologically based pharmacokinetic modeling

Dabigatran etexilate (DABE) is a direct oral anticoagulant (DOAC) and may be combined with ticagrelor, a P2Y(12) inhibitor with antiplatelet effects. This combination of antiplatelet drugs and anticoagulants would increases the risk of bleeding in patients. In addition, the potential drug interactio...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Nan, Chen, Lu, Li, Na, Xu, Gaoqi, Qi, Fang, Zhu, Liqin, Liu, Wensheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298054/
https://www.ncbi.nlm.nih.gov/pubmed/32546773
http://dx.doi.org/10.1038/s41598-020-66557-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298054/
https://www.ncbi.nlm.nih.gov/pubmed/32546773
http://dx.doi.org/10.1038/s41598-020-66557-x

Ejemplares similares